Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × tucatinib × Gynecologic × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡